By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intrexon Corporation (South San Francisco, CA) 

201 Industrial Road, Suite 420
San Carlos, California 94070

201 Gateway Boulevard, 1st Floor
South San Francisco  California  94080  U.S.A.
Phone: n/a Fax: n/a

Founded in 1998, Intrexon Corporation is a privately held biotechnology company focused on the industrial engineering of synthetic biology. Intrexon is deploying its extensive capabilities to rapidly design and produce novel and enhanced biological products and processes across multiple industry sectors, including: human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science. The company’s advanced bioindustrial engineering platform enables Better DNA™ technology by combining breakthroughs in DNA control systems with corresponding advancements in modular transgene design, assembly, and optimization to enable unprecedented control over the function and output of living cells.

Our mission is to redefine the biotechnology development process by engineering complex multigenic biological and cellular systems at unprecedented scale, dramatically reducing the time, cost, and risks associated with synthetic biology. With an extensive and expanding patent portfolio, Intrexon is working with key channel partners throughout our commercial divisions to utilize the industrial engineering of synthetic biology in developing new products and processes, which will alleviate shortages of essential nutrients, bring better medicines to more people, and generate renewable fuels and other resources. Our Better DNA™ technology provides the foundation to industrialize the development of high-performing biological products and enable many new possibilities across broad industries.

Intrexon’s commercial and core technology divisions are located within the country’s major biotechnology hotbeds. In California, San Francisco is the primary site of the Protein Production and Industrial Products Divisions, with our Cell Engineering Unit nearby in San Diego. Intrexon’s expansive Germantown, Maryland facility is centrally located within the Mid-Atlantic biotech region and is currently home to our Human Therapeutics and Animal Science Divisions, as well as our Molecular Engineering Unit. Corporate headquarters, as well as the UltraVector Technology Division are both located in Blacksburg, Virginia. Finally, the southern states host a second site for our Protein Production Division in Charleston, South Carolina, in addition to our Agricultural Biotech Division in Research Triangle Park, North Carolina.

We are always seeking those who share our passion for excellence, hard work, creativity, and moving beyond the limitations of traditional biotech. ?With Intrexon you will have an exceptional opportunity to join the forefront of the bioindustrial revolution and contribute directly to the future of synthetic biology applications and products.

Please visit for further information on our company.

Key Statistics

Ownership: Private

Web Site: Intrexon Corporation (South San Francisco, CA)


Company News
Merck Serono, Intrexon Corporation Ink $941M Pact, As Race for CAR-T Edge Continues 3/30/2015 10:03:41 AM
Histogenics Corporation And Intrexon Corporation Announce Formation Of Exclusive Channel Collaboration For Cartilage Repair Therapies 10/3/2014 7:40:56 AM
Intrexon Corporation And Amneal Pharmaceuticals Expand Relationship With Second Product Collaboration 10/2/2014 9:17:37 AM
Fibrocell Science, Inc. And Intrexon Corporation Advance GM-HDF-COL7 Toward Clinical Development For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa 9/24/2014 8:59:52 AM
Intrexon Corporation Announces The Appointment Of Keith Canada As Vice President, UltraVector® Division 9/5/2014 9:52:52 AM
Intrexon Corporation Announces Exclusive Channel Collaboration With Sanofi (France) (SAN.PA) To Optimize Production For A Specific Family Of Active Pharmaceutical Ingredients 9/2/2014 1:39:17 PM
Intrexon Corporation Enters Into Technology Collaboration To Advance Animal Health Applications 7/29/2014 8:15:25 AM
Intrexon Corporation Announces First Quarter Financial Results 5/8/2014 6:49:32 AM
Synthetic Biologics, Inc. (SYN)' Reports Preclinical Data To Support Clinical Development Of Novel Pertussis Therapeutic 4/23/2014 9:01:34 AM
Codexis, Inc. (CDXS) Sells Its Hungarian Operations To Intrexon Corporation 3/14/2014 9:17:27 AM